Express Pharma

COVID-19 trials and tribulations for treatments

Dr Arun Bhatt, Consultant – Clinical Research & Drug Development states that in the absence of a peer-reviewed publication in a reputed journal, it is difficult to judge the risk-benefit of the 2-Deoxy-D-Glucose in treating seriously ill COVID-19 patients. He also emphasises that it would be desirable to investigate Indian innovations in high-quality clinical trials planned based on globally acceptable scientific and ethical principles

0 680